Does Novo Nordisk’s slimmed down rebrand signal a new era of DTC revivalism?
Novo Nordisk, the Dandish drugmaker behind the weight-loss drugs Ozempic and Wegovy, announced it’s rebranding to “Novo” beginning this week. It’s part of a larger trend in healthcare branding . The rise of telehealth, direct-to-consumer pharmaceutical companies, and consumer-facing GLP-1s has drugmakers rebranding their once sterile brands to something more friendly. Novo Nordisk is no…
Novo Nordisk, the Danish pharmaceutical company behind the popular weight-loss drugs Ozempic and Wegovy, is undergoing a slimmed-down rebranding to "Novo" beginning this week. The company aims to connect with a younger, more market-savvy consumer base and compete with direct-to-consumer pharmaceutical brands that deliver drugs online.
The new visual identity features a modern sans-serif font for the shortened name, a simplified Apis bull logo, and a refreshed color palette with cobalt blue and bright turquoise accents. The company also rolled out a new tagline, "Lasting Health Starts Now," to present itself as more approachable and relevant. Novo Nordisk's CEO, Mike Doustdar, emphasized that people's expectations of healthcare are evolving, and the brand must become more responsive and easier to fit into everyday life.
This rebranding reflects a broader trend in healthcare branding, where traditional, clinical names are being replaced with friendlier, more human-centric identities to appeal to consumers seeking convenient, personalized medical solutions.
Written by urgent.news from Fast Company's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
